(Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp ® Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S ...

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...

Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. The median survival ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...

After being diagnosed with chronic myeloid leukemia, graphic designer Aaron von Freter was able to participate in a clinical trial that offered him hope of being cured. When Aaron von Freter learned ...

The latest research on chronic myeloid leukemia (CML) presented at the 2024 American Society of Hematology 2024 Annual Meeting and Exposition is reported by Dr Jorge Cortes from Georgia Cancer Center ...

Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...